Men often meet the healthcare system episodically—insurance change, a gym challenge, or a viral "optimize your bloodwork" thread. A calmer approach: understand a few high-yield markers, know their limits, and partner with a clinician on timing and follow-up. For a deeper dive on testosterone specifically, see what your testosterone lab results actually mean.
What it is (the five)
- Morning total testosterone (and free T/SHBG when indicated)
- A1C and/or fasting glucose (glycemic health)
- Atherogenic lipids (at least LDL-C; often a full lipid panel)
- Hematocrit (via CBC)—especially relevant if testosterone therapy is considered or ongoing
- PSA — when age, risk, and shared decision-making support checking
These are not the only useful labs (blood pressure is vital and not a "lab"; TSH, ALT/AST, kidney function, and sleep apnea evaluation matter too).
How it works
Testosterone. Levels vary by time of day and health status. Endocrine Society guidance: do not diagnose hypogonadism from symptoms alone or from a single unverified low; confirm morning values and interpret with signs/symptoms. Routine screening of asymptomatic men is not recommended.
A1C / glucose. Reflect average glycemia (A1C) or current fasting glucose. Central to diabetes/prediabetes detection and to metabolic risk that also influences SHBG and endogenous testosterone.
Lipids. LDL-C and related measures inform atherosclerotic cardiovascular disease risk discussions; therapy thresholds depend on overall risk, not a single birthday.
Hematocrit. Percentage of blood that is red cells. Testosterone stimulates erythropoiesis; monitoring matters on TRT (MedlinePlus hematocrit education; product labels/guidelines).
PSA. Prostate-produced protein. Elevation has many causes (enlargement, infection, recent ejaculation, cancer). It is a risk marker/discussion tool—not a stand-alone cancer diagnosis (MedlinePlus).
What evidence shows
| Marker | Established use | Common overclaim |
|---|---|---|
| Testosterone | Diagnose/monitor hypogonadism with clinical context | "Optimize to bodybuilder ranges" |
| A1C/glucose | Detect/monitor dysglycemia | Ignoring it while focusing only on T |
| Lipids | CV risk assessment | Assuming "I'm on TRT so lipids don't matter" |
| Hematocrit | Safety monitoring especially on T | One-time check forever |
| PSA | Shared decision screening / monitoring contexts | Using PSA alone to start/stop TRT without clinician judgment |
TRAVERSE and FDA labeling updates refined cardiovascular risk communication for testosterone products; they did not make labs optional.
Risks
- Over-testing without a plan (incidentalomas of interpretation)
- Under-testing before starting hormones or weight-loss drugs
- Biotin and other interferences with some assays
- Anxiety from red flags without clinical follow-up
- Missing blood pressure—often more actionable than a borderline estradiol post on social media
Who should discuss with a clinician
Men over 30 with fatigue, sexual symptoms, unexplained weight change, family history of early heart disease or diabetes, obesity, or interest in TRT/GLP-1 therapies. African American men and those with first-degree relatives with prostate cancer should discuss prostate risk earlier in shared decision-making (per Endocrine Society discussion points around TRT).
Digging deeper on each marker
1. Testosterone (done the boring, correct way)
Ask for the draw time on the report. Afternoon "low" results are common and often misleading. If total T is near the lower limit or you have obesity/thyroid/liver issues that change SHBG, ask whether free testosterone (ideally a high-quality method) adds clarity. Bring a symptom list: libido, morning erections, energy, mood, strength—guidelines still require clinical context, not a trophy number.
2. A1C / fasting glucose
Prediabetes is easy to miss when the conversation is only about hormones. Insulin resistance also tends to lower SHBG, which can change how total T looks. If you are considering GLP-1 therapy, glycemic labs help establish baseline and safety monitoring with your clinician.
3. Lipids
A standard lipid panel is a foundation for cardiovascular risk discussion. TRT and weight change can both shift lipids in individual men; neither replaces guideline-directed lipid care when risk is high.
4. Hematocrit (CBC)
Know your baseline before any testosterone exposure. Rising hematocrit is one of the more actionable safety signals on therapy. Hydration, dose, sleep apnea, and smoking history all influence interpretation—another reason blogs cannot manage your CBC.
5. PSA in shared decision-making
Guidelines around prostate evaluation before/during TRT emphasize discussion, especially ages ~55–69 or higher-risk groups. A single PSA does not diagnose cancer; a rising pattern or abnormal exam prompts urologic follow-up pathways described in Endocrine Society monitoring recommendations.
Bottom Line
Five markers—testosterone (done properly), glycemia, lipids, hematocrit, and context-appropriate PSA—cover a large share of men's midlife metabolic and hormone conversations. Numbers need narrative: sleep, meds, family history, and goals.
So what?
At your next visit, ask which of these you already have on file from the past year and which should be repeated morning/fasting before any hormone decision.
If you want to see how Scoreboard Health incorporates baseline and follow-up labs into men's care pathways, visit How it works or Treatments.
Related reading
Disclaimer: Educational only. Not medical advice or a personal screening schedule. Compounded medications are not FDA-approved.
Medically reviewed by: Ana Argote, BSN, R.N.
Sources
- Endocrine Society testosterone guideline (2018). endocrine.org · PubMed
- MedlinePlus. Testosterone Levels Test. medlineplus.gov
- MedlinePlus. Hematocrit Test. medlineplus.gov
- MedlinePlus. PSA Test. medlineplus.gov
- U.S. FDA. Testosterone class-wide labeling changes (2025). fda.gov
- Lincoff AM, et al. TRAVERSE. N Engl J Med. 2023. nejm.org
Learn how Scoreboard Health structures men's evaluation pathways: How it works · Treatments